Brexpiprazole is a drug used to either treat Schizophrenia or to prevent its relapse. It is also approved for use as an adjuvant in the treatment of Major Depressive Disorder (MDD), as an add-on when first line antidepressants fail to provide sufficient clinical results. Brexpiprazole has been launched under the brand name Rexulti. Brexpiprazole was[…]
Brexpiprazole: A Molecule That Should Be On Your Radar
Antidepressant, Antipsychotic Tags: BrexpiprazoleSchizophrenia Mar 27, 2017
FDA Approves Unique Multimodal Vortioxetine for Major Depressive Disorder
Antidepressant, FDA Approved 2013 Tags: Major Depressive DisorderserotoninSSRI Oct 07, 2013
The approval of Vortioxetine CAS# 508233-74-7 came as exciting news at the close of September 2013. Known as the brand name Brintellix, Vortioxetine is marketed by Lundbeck and Takeda Pharmaceuticals. The FDA approval of this antidepressant is encouraging for both patients suffering from Major Depressive Disorder and the practitioners who treat these patients, as Vortioxetine[…]
FDA Approves New Antidepressant Levomilnacipran
Antidepressant, Drug Research & Development API Tags: AntidepressantMajor Depressive Disorderserotonin Aug 01, 2013
Levomilnacipran, CAS number 96847-55-1, has been a headline in the recent pharmaceutical news. This headline status is due to the FDA approval of Fetzima, the brand name for Levomilnacipran, at the end of July 2013. Approved as a medication to treat major depressive disorder in adults, Levomilnacipran is designed as a once daily dose. As[…]
Escitalopram Prevents Mental Stress-Induced Myocardial Ischemia in Patients with Coronary Artery Disease
Antidepressant, Drug Research & Development API Tags: AntidepressantSSRI Jun 10, 2013
On May 29, 2013 the researchers from Duke Medicine revealed new findings about the benefits of the antidepressant Escitalopram CAS# 128196-01-0. Known as the brand name Lexapro, Escitalopram has long been touted as an efficacious and safe treatment for clinical depression. The latest findings regarding Escitalopram, reported in The Journal of the American Medical Association,[…]
Will Once Weekly Fluoxetine Help Create New Brain Cells?
Antidepressant, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2017, TEVA API Tags: Antidepressantserotonin Jan 23, 2013
The expiration for the patent of the new formulation of Prozac, also known as the generic drug Fluoxetine Hydrochloride, is slated for November 1, 2017. As a common and effectual antidepressant, Fluoxetine HCl CAS# 56296-78-7, has proven to be a valuable treatment for patients in the United States and worldwide. In fact, antidepressant use in[…]
Vilazodone is an SSRI that Does Not Affect Sexual Function
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI Nov 27, 2012
Vilazodone is in a class of medications called selective serotonin reuptake inhibitors, or SSRIs, and is also a 5HT1A receptor partial agonist. Known as the brand name Viibryd, this medication was approved in January of 2011 to treat Major Depressive Disorder in adults. In safety studies involving 2,177 patients the most common adverse side effects[…]
An Overview of Why Paroxetine Hydrochloride is Effective and Useful
Antidepressant, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015, TEVA API Tags: AntidepressantserotoninSSRI Aug 30, 2012
Paroxetine Hydrochloride, known by the trade name Paxil, has an upcoming patent expiration date of May 19, 2015. As a well used medication to treat depression, Paroxetine HCl, CAS number 78246-49-8, is projected to become a generic powerhouse. Paroxetine is efficacious at treating not only major depression, but also obsessive compulsive disorder, panic disorder, social[…]
Duloxetine Hydrochloride Effectual for Osteoarthritis Pain Management
Antidepressant, Drug Research & Development API, Patent Expiration 2013 Tags: Antidepressantserotonin May 29, 2012
Duloxetine Hydrochloride CAS# 136434-34-9, is also known as the brand name Cymbalta marketed by Lilly. This effective antidepressant will be going off patent in June of 2013. Duloxetine hydrochloride is currently approved to treat the following: clinical depression; peripheral diabetic neuropathy pain, or nerve pain in the hands, feet, arms, and legs from diabetes; generalized[…]
Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI May 02, 2011
Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year. The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]
Pizotifen for Headaches & Psychosomatic Illnesses
Analgesic, Antidepressant, Drug Research & Development API Dec 02, 2010
Pizotifen Uses: Pizotifen, also known as pizotylin, is a preventive medicine based on benzocycloheptane, that is used to prevent or to reduce the occurrence of migraine attacks, vascular headache and cluster tension headaches. Pizotifen can also be used as anti-depressant to cure social phobia and anxiety. Pizotifen is usually considered as an effective treatment for migraine prevention[…]
